Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Core Viewpoint - The company, 佛慈制药, is focusing on expanding its international presence by leveraging its export advantages and increasing investments in overseas operations [1] Group 1: International Expansion - The company's products have been exported to 32 countries and regions [1] - The number of overseas product registrations has reached 1,442, indicating a strong foothold in international markets [1] - The company maintains a leading position in the industry regarding the number of foreign certifications, overseas trademark registrations, and the range of exported products [1] Group 2: Strategic Initiatives - The company plans to deepen its international strategic layout by enhancing overseas construction investments [1] - Efforts will be made to promote international product registration and compliance certification [1] - The company aims to strengthen promotion through brand co-construction and channel sharing to continuously expand its overseas market share [1]

Group 1 - The core viewpoint of the article is that the company, 佛慈制药, is making a strategic investment in 科近泰基新技术有限公司 to enhance its position in the radioactive isotope pharmaceutical sector [1] - The company plans to invest 20 million yuan by October 2025 to participate in the capital increase of 科近泰基, which is a wholly-owned subsidiary of the Chinese Academy of Sciences [1] - The main business of 科近泰基 includes the production, sales, operation, and collaborative research and development of medical isotopes such as α-radioactive isotopes 225Ac and 223Ra [1] Group 2 - This investment aims to seize opportunities in the precision radiotherapy industry and strengthen the company's innovation drive [1] - The move is expected to inject new momentum into the company's long-term development [1]

Group 1: Company Performance and Strategy - The company plans to disclose its 2025 annual report on April 9, 2026, detailing specific operational performance [2] - The company aims to strengthen its core product system and enhance brand influence by focusing on traditional products and unique varieties [2] - The company has a reasonable inventory level, with turnover rates aligning with industry standards [5] Group 2: Market Expansion and Investment - The company has been exporting since 1931 and currently sells products in 32 countries, with 1,442 overseas product registrations [4] - In October 2025, the company invested 20 million yuan in KJT Technology Co., Ltd. to enter the radioactive isotope drug sector [5] - The company is committed to enhancing its international strategy and expanding its overseas market share [4] Group 3: Future Development Plans - During the 14th Five-Year Plan, the company will focus on modernizing and internationalizing traditional Chinese medicine [6] - The company aims to optimize production line structures and enhance technological innovation to strengthen its core competitiveness [6]

Core Viewpoint - The company has not established any collaboration with ByteDance's Doubao, but remains attentive to new technologies and business models that align with its main business direction, indicating a willingness to explore relevant fields in the future [1]. Group 1 - The company has clarified its current lack of partnership with ByteDance's Doubao [1]. - The company is focused on new technologies and business models that fit its main business direction [1]. - The company plans to actively explore relevant fields when opportunities arise [1].

Core Viewpoint - The company has not established any collaboration with ByteDance's Doubao, but remains attentive to new technologies and business models that align with its main business direction, indicating a willingness to explore relevant fields in the future [1] Group 1 - The company is currently not in partnership with ByteDance's Doubao [1] - The company is focused on new technologies and business models that fit its main business direction [1] - The company plans to actively explore relevant fields when opportunities arise [1]

Group 1 - The company has established an official flagship store on the Tmall platform and maintains a long-term stable e-commerce business collaboration with Alibaba Health [2] - Specific information will be provided in the company's annual report and related announcements [2]

Core Viewpoint - The company, 佛慈制药, confirmed that it will not benefit from the new tax policy regarding advertising and business promotion expenses, as the tax treatment remains consistent with previous regulations [1] Group 1: Tax Policy Impact - The Ministry of Finance and the State Administration of Taxation announced a new policy on December 29, 2023, regarding the tax deduction for advertising and business promotion expenses, effective from January 1, 2026, to December 31, 2027 [1] - 佛慈制药 stated that the tax policy related to advertising and business promotion expenses will remain unchanged for the company, indicating no additional benefits from the new policy [1]

兰州佛慈制药股份有限公司 董事、高级管理人员持有和买卖本公司股票管理制度 第一章 总则 第一条 为规范兰州佛慈制药股份有限公司（以下简称"公司"） 董事、高级管理人员持有及买卖本公司股票行为，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司董事、高级管理人员所持本 公司股份及其变动管理规则》（以下简称"《管理规则》"）《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》（以下简称"《规范运作指引》"）等法律、法规、规范性文件 以及《兰州佛慈制药股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，结合公司的实际情况，特制定本制度。 第二条 公司董事、高级管理人员所持本公司股份，是指登记在 其名下和利用他人账户所持有公司股份。从事融资融券交易的，还包 括记载在其信用账户内的公司股份。 第三条 公司及董事、高级管理人员在买卖公司股票及其衍生品 种前，应知悉相关法律、法规、规范性文件中关于内幕交易、短线交 易、窗口期交易、限售期出售股票和操纵市场等禁止行为的规定，不 得进行违法违规的交易。 第二章 股份登记申报和锁定 ...

兰州佛慈制药股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为规范兰州佛慈制药股份有限公司（以下简称"公司"） 重大信息内部报告工作，保证公司内部重大信息快速传递、归集和有 效管理，及时、准确、全面、完整地披露信息，维护投资者的合法权 益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司信息披露管理办法》《深圳证券交易所股票上市规则》（以下 简称"《股票上市规则》"）及《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》（以下简称"《规范运作指 引》"）等法律、法规、规范性文件以及《兰州佛慈制药股份有限公 司章程》（以下简称"《公司章程》"）《兰州佛慈制药股份有限公 司信息披露管理制度》（以下简称"《信息披露管理制度》"）的有 关规定，结合公司实际情况，特制定本制度。 第二条 本制度所指重大信息是指根据法律、行政法规、部门规 章、规范性文件和深圳证券交易所其他相关规定应当披露的，对公司 证券及其衍生品种交易价格可能或者已经产生较大影响的信息。 第三条 公司重大信息内部报告制度是指当出现、发生或即将发 生可能对公司证券及其衍生品种交易价格产生较大影响的信息时，按 ...